-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is from the NEJM Journal Watch Real-World
Usage of Semaglutide Leads to Substantial Weight Loss: Significant Weight Loss
Review by Thomas L.
Schwenk, MD, Molly S.
Brett, MD
Even with little dietary education and support, weight loss at 3 and 6 months was similar
to that in controlled trials.
Semeglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally used to treat type 2 diabetes, has led to substantial weight
loss in randomized trials.
In this retrospective study, Mayo Clinic researchers evaluated the effects
of semeglutide for obesity in a less controlled setting.
The investigators identified 408 patients who were prescribed semeglutide (weekly subcutaneous injection) (mainly for weight loss); More than half of these patients were excluded from the study for reasons such as insurance company refusal to cover coverage, drug shortages, previous bariatric surgery, use of other bariatric drugs, or active malignancy
.
In the remaining 175 patients (mean age, 49 years; 16% had type 2 diabetes; Average body mass index, 41 kg/m2), only 1/4 received dietary counselling, and 10% received some type of psychological support
.
By 3 months, half had lost more than 5% of their body weight and 15% had lost more than
10%.
Of the 102 patients who received 6-month follow-up, almost all lost more than 5 percent, half lost more than 10 percent, and one in four lost more than
15 percent.
Counseling a dietitian or psychologist was not associated
with greater weight loss.
Almost half of the patients achieved the maximum dose (1.
7 mg or 2.
4 mg per week); People who achieved these doses had significantly greater weight loss (compared to smaller doses), but there was little clinical difference
.
These real-world results were good compared to results in randomised trials, even when
dietary and psychological support was minimal.
Some clinics require patients to participate in lifestyle intervention programs to receive weight-loss medications, but the study suggests that semeglutide is effective
even without these supports.
Notably, more than one-third of patients with a prescription for semeglutide were excluded from the trial due to insurance company refusal to cover or a shortage of the drug, two major barriers
physicians face when prescribing the drug and other weight-loss drugs to patients.
Articles that are commented on
.
NEJM Medical Frontiers is translated several times a week, published on the app and official website, and selected 2-3 articles are published
on WeChat.
Copyright Information This article is translated, written or commissioned
by Jiahui Medical Research and Education Group (J-Med) and the New England Journal of Medicine (NEJM).
The full Chinese translation and the figures contained therein are exclusively licensed
by NEJM Group.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement and the copyright owner reserves the right to
pursue legal responsibility.
Usage of Semaglutide Leads to Substantial Weight Loss: Significant Weight Loss
Review by Thomas L.
Schwenk, MD, Molly S.
Brett, MD
Even with little dietary education and support, weight loss at 3 and 6 months was similar
to that in controlled trials.
Semeglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally used to treat type 2 diabetes, has led to substantial weight
loss in randomized trials.
In this retrospective study, Mayo Clinic researchers evaluated the effects
of semeglutide for obesity in a less controlled setting.
The investigators identified 408 patients who were prescribed semeglutide (weekly subcutaneous injection) (mainly for weight loss); More than half of these patients were excluded from the study for reasons such as insurance company refusal to cover coverage, drug shortages, previous bariatric surgery, use of other bariatric drugs, or active malignancy
.
In the remaining 175 patients (mean age, 49 years; 16% had type 2 diabetes; Average body mass index, 41 kg/m2), only 1/4 received dietary counselling, and 10% received some type of psychological support
.
By 3 months, half had lost more than 5% of their body weight and 15% had lost more than
10%.
Of the 102 patients who received 6-month follow-up, almost all lost more than 5 percent, half lost more than 10 percent, and one in four lost more than
15 percent.
Counseling a dietitian or psychologist was not associated
with greater weight loss.
Almost half of the patients achieved the maximum dose (1.
7 mg or 2.
4 mg per week); People who achieved these doses had significantly greater weight loss (compared to smaller doses), but there was little clinical difference
.
These real-world results were good compared to results in randomised trials, even when
dietary and psychological support was minimal.
Some clinics require patients to participate in lifestyle intervention programs to receive weight-loss medications, but the study suggests that semeglutide is effective
even without these supports.
Notably, more than one-third of patients with a prescription for semeglutide were excluded from the trial due to insurance company refusal to cover or a shortage of the drug, two major barriers
physicians face when prescribing the drug and other weight-loss drugs to patients.
Articles that are commented on
Ghusn W et al.
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity.
JAMA Netw Open 2022 Sep 19; 5:e2231982.
(https://doi.
org/10.
1001/jamanetworkopen.
2022.
31982)
NEJM Journal Collection
Published by NEJM Group, NEJM Journal Watch invites internationally renowned doctors to review important papers in the medical field to help doctors understand and apply the latest developments.
NEJM Medical Frontiers is translated several times a week, published on the app and official website, and selected 2-3 articles are published
on WeChat.
Copyright Information This article is translated, written or commissioned
by Jiahui Medical Research and Education Group (J-Med) and the New England Journal of Medicine (NEJM).
The full Chinese translation and the figures contained therein are exclusively licensed
by NEJM Group.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement and the copyright owner reserves the right to
pursue legal responsibility.
